Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6606 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-01 (biopharmadive.com)
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda |
Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics production plant.
Read more
2025-05-01 (bloomberg.com)
Biogen Lowers Profit Outlook After Deal for Epilepsy Drug
cut its profit guidance for the year to reflect the cost to acquire the rights to a genetic seizure disorder drug.
Read more
2025-04-14 (centerforbiosimilars.com)
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Read more
2025-04-03 (femtechinsider.com)
What's New in Femtech This Week? (April 3, 2025) | Femtech Insider
Every Thursday we send out a curated newsletter on all things femtech and women's health innovation. This is an excerpt from the latest edition. If you'd like to subscribe, you can do so at the bottom of this page. Highlights Women's healthtech company Fizimed raises €4M for international expansion. PE Firm Astorg combined multiple reproductive health medtech businesses; launches Nexpring Health.
Read more